| 23-Sep-2009 | S | Gennex Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on September 22, 2009, inter alia, has passed the following resolution:
'It has been resolved that the proposal to split the existing Equity Shares of face value of Rs. 10/- each into Equity Shares of face value of Rs. 1/- each in accordance with the provisions of Section 94(1)(d) of the Companies Act, 1956, as provided for in the Article 9(b) of the Articles of Association of the Company, be placed for approval at the Company's next Extra Ordinary General Meeting schedule to be held on October 31, 2009. The Board has also authorised the Chairman to complete all the requisite formalities like ballot posting etc.'
Gennex Laboratories Ltd has informed BSE that the members at the Extra Ordinary General Meeting (EGM) of the Company held on October 31, 2009, have approved 1,60,00,000 equity shares of the nominal value of Rs. 10/- each in the authorized capital of the Company be sub-divided into 16,00,00,000 equity shares of Rs. 1/- each and that Clause V (being capital Clause) of the Memorandum of Association and Article 3 of the Articles of Association of the Company relating to equity shares b altered accordingly.
(As Per BSE Announcement Dated on 02/11/2009)
SUB. :- Sub Division of equity shares of Gennex Laboratories Limited (Scrip Code 531739)
Trading Members of the Exchange are hereby informed that, Gennex Laboratories Ltd. has fixed the Record Date for the purpose of sub division of equity shares of the company.
DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT
COMPANY NAME & CODE
Gennex Laboratories Ltd. (531739)
RECORD DATE
15/12/2009
PURPOSE
Sub Division of existing equity shares from every ONE equity share of Rs.10/- each into TEN equity shares of Re.1/- each.
SUB-DIVIDED PAID-UP VALUE
Re.1/-
SUB-DIVIDED PAID-UP VALUE W.E.F.
14/12/2009 DR- 175/2009-2010
Note :-
i. Trading members are hereby informed that the transactions in the equity shares (physical) of the aforesaid company in the Exit-Route Scheme will be for Re.1/- paid up w.e.f. 14/12/2009.
ii. ISIN No. INE509C01018 of Rs.10/- paid up will not be valid for transactions done on the Exchange on or after 14/12/2009.
iii. The new ISIN Number for Re.1/- paid up will be informed to the market by a separate notice.
(As Per BSE Notice Dated on 01.12.2009) | 15-Dec-2009 | |
| 18-Jul-2022 | R | 1:2 Right Issue of Equity Shares
Trading Members of the Exchange are hereby informed that, Gennex Laboratories Ltd has fixed Record Date for the purpose of Rights Issue of Equity Shares. The transactions in the Equity Shares of the Company should be done on Ex-Rights basis with effect from the under mentioned date :-
DEMATERIALISED SECURITIES - ROLLING SETTLEMENT SEGMENT
COMPANY NAME
& CODE
Gennex Laboratories Ltd
(531739)
RECORD DATE
22/07/2022
PURPOSE
Issue of 1 (One) Equity Share of Re. 1/- each for Cash at a premium of Rs. 5/- on rights basis for every 2 (Two) fully paid-up Equity Shares held.*
Ex-Right basis from Date & Sett. No.
21/07/2022
DR-079/2022-2023
* Note: Issue Price - Rs.1.50 (including Premium of Rs.1.25) to be paid on Application and balance Rs.4.50 (including Premium of Rs.3.75) to be paid on First and Final Call.
(As Per BSE Notice Dated on 19.07.2022) | 22-Jul-2022 | 1:2 |
| 19-Mar-2024 | BC | Trading members of the Exchange are hereby informed that the under mentioned new securities of Gennex Laboratories Ltd (Scrip Code - 531739) are listed and permitted to trade on the Exchange with eff | 20-Mar-2024 | |
| 01-Feb-2024 | BC | GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve 1. Consider and adopt the Unaudited Fi | 14-Feb-2024 | |
| 02-Feb-2024 | BC | This has reference to your email dated 02/02/2024 regarding additional details required for corporate announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015 with Discrepancies: Addit | 14-Feb-2024 | |
| 27-Jan-2024 | BC | Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 read with Schedule III thereto, and in furtherance to our intimation dated 20/11/2023, 29/11/2023, and Board meeting outcome filed on 02 | 27-Jan-2024 | |
| 04-Dec-2023 | BC | Pursuant to Regulation 42 of SEBI (LODR) Regulations, 2015, the Register of Members and Share Transfer Books of the Company will remain closed from 24.12.2023 to 30.12.2023 (both days inclusive) for | 30-Dec-2023 | |
No Dividends has been declared by GENNEXLABORATORIES
No Bonus has been declared by GENNEXLABORATORIES
Record Date15-Dec-2009
Split Date14-Dec-2009
Face Value (Before/After)10/1
RightsRecord Date01 Jan'1900
Ex-Rights Date01 Jan'1900
Premium(Rs.)5
Ratio1:2
Book Closure
| 20-Mar-2024 | - | Trading members of the Exchange are hereby informed that the under mentioned new securities of Gennex Laboratories Ltd (Scrip Code - 531739) are listed and permitted to trade on the Exchange with eff |
| 14-Feb-2024 | - | GENNEX LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve 1. Consider and adopt the Unaudited Fi |
| 14-Feb-2024 | - | This has reference to your email dated 02/02/2024 regarding additional details required for corporate announcement filed under Regulation 30 of SEBI (LODR) Regulations, 2015 with Discrepancies: Addit |
| 27-Jan-2024 | - | Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 read with Schedule III thereto, and in furtherance to our intimation dated 20/11/2023, 29/11/2023, and Board meeting outcome filed on 02 |
| 30-Dec-2023 | - | Pursuant to Regulation 42 of SEBI (LODR) Regulations, 2015, the Register of Members and Share Transfer Books of the Company will remain closed from 24.12.2023 to 30.12.2023 (both days inclusive) for |